Thirty seven black Kenyans aged 30-69 attending a hospital clinic for hypertension were admitted to this double blind crossover trial. All treatment was withdrawn for a minimum of two weeks, after which inclusion in the trial depended on a diastolic blood pressure > 105 mm Hg. This was followed by four weeks of treatment with a diuretic (hydrochlorothiazide 25 mg once daily), when those whose diastolic blood pressure fell below 90 mm Hg were withdrawn from the trial. Patients were then randomly allocated, in balanced blocks of four, to six weeks' treatment with either diuretic plus slow release nifedipine 20 mg twice daily or diuretic plus propranolol 80 mg twice daily. After another four weeks of treatment with diuretic alone the study treatments were crossed over.
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Patients, methods, and results
Thirty seven black Kenyans aged 30-69 attending a hospital clinic for hypertension were admitted to this double blind crossover trial. All treatment was withdrawn for a minimum of two weeks, after which inclusion in the trial depended on a diastolic blood pressure > 105 mm Hg. This was followed by four weeks of treatment with a diuretic (hydrochlorothiazide 25 mg once daily), when those whose diastolic blood pressure fell below 90 mm Hg were withdrawn from the trial. Patients were then randomly allocated, in balanced blocks of four, to six weeks' treatment with either diuretic plus slow release nifedipine 20 mg twice daily or diuretic plus propranolol 80 mg twice daily. After another four weeks of treatment with diuretic alone the study treatments were crossed over.
Blood pressure was measured with a random zero sphygmomanometer by one of three observers whose technique had been standardised beforehand. At each visit blood pressure was recorded twice after five minutes' lying down, a radial pulse being measured between readings, and blood pressure and radial pulse were recorded after two minutes' standing. Patients were seen every two weeks throughout the trial. At the start of the trial and at the end of each stage patients were weighed and full biochemical blood screens, including plasma renin activity, were carried out. Plasma renin activity was estimated (after standardised sampling) by radioimmunoassay of angiotensin I generated by incubating plasma for four hours. Results were analysed with Student's t test for paired data and Hills and Armitage's method for analysing data from crossover trials.3
Five patients were withdrawn after responding to diuretic treatment alone. Another patient withdrew because of work commitments, and two were withdrawn while taking propranolol (one patient's diastolic blood pressure rose above 125 mm Hg and one had symptoms suggesting heart failure). Of the 29 remaining patients, 16 initially took nifedipine plus diuretic. This combination produced significantly lower systolic and diastolic blood pressures than propranolol plus diuretic (p < 0 05) (table). Both combinations of drugs significantly reduced blood pressure compared with diuretic alone (p < 005).
There were no significant changes in the patients' mean weight and serum creatinine and sodium concentrations throughout the trial. Serum uric acid and blood urea concentrations rose and serum potassium fell significantly during diuretic treatment, suggesting good compliance (confirmed by pill counts and the changes in pulse rates). Plasma renin activity was low and changed with treatment (table). Twenty two patients' lying mean arterial blood pressure and 19 patients' standing mean arterial blood pressure fell more with nifedipine than with propranolol. Although those whose blood pressure fell more when nifedipine was added to diuretic had a lower mean plasma renin activity (047 (SD 060) nmolWh), these differences were not significant (t test BMJ VOLUME 306hypertensive patients.' In this study nifedipine plus diuretic lowered blood pressure more effectively than propranolol plus diuretic, which has previously been shown to be effective in black hypertensive patients. Patient years of observation were measured from the first date of a prescription up to the patient's death or 31 October 1990. Mortalities from cancer (cancer given as the underlying cause of death) were calculated for each treatment and were adjusted for age by the direct method. We compared the risks between treatments with the Cox proportional hazards model, adjusting for age and smoking. We performed a nested case-control study of deaths from lung cancer, matching 79 cases (58 men and 21 women: 68 with lung cancer given as the underlying cause of death and 11 with any mention of lung cancer on the death certificate) with 154 controls. We also calculated standardised mortality ratios for all hypertensive patients.
There was no evidence for an adverse relation between atenolol and all cancers or lung cancer (table) . Adjustment of the relative risks for smoking made little difference. Women taking atenolol appeared to be at lower risk of lung cancer, but the number of deaths was small and confidence intervals wide. There was no evidence that treatment had different effects on men and women. Blood pressure (whether treated or untreated, systolic or diastolic) showed no relation with deaths from all cancers or lung cancer.
A conditional multiple logistic regression analysis of our case-control study gave a relative risk from smoking of 4-2 (95% confidence interval 1 9 to 9 0, p < 0 0004) and from atenolol treatment of 0 9 (0 4 to 2-1, p=0 7). The only excess standardised mortality ratio was for renal cancer (ICD codes 1890-9) with a value of 196 (107 to 328, p=0 03) for men and women combined.
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